Non-camptothecin topoisomerase I active compounds as potential anticancer agents

Bibliography

• POMMIER Y: Diversity of DNA topoisomerases I and inhibitors,. Biochimie (1998) 80:255–270.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of topo I and its inhibitors.
   Google Scholar
• POMMIER Y, POURQUIER P, FAN Y, STRUMBERG D: Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta (1998) 1400:83–105.
   PubMed Web of Science ®Google Scholar
• POMMIER Y: DNA topoisomerase II inhibitors. In Cancer Therapy. Teicher BA, (Ed.) Totowa NJ: Humana (1997):153–174.
   Google Scholar
• CHEN AY, LIU LF: DNA topoisomerases: essential enzymes and lethal targets. Ann. Rev. Pharmacol. Toxicol (1994) 34:191–218.
   PubMed Web of Science ®Google Scholar
• BAILLY C: Topoisomerase I poisons and suppressors as anticancer drugs. Curr. Med. Chem. (2000) 7:39–58.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of topo I and its inhibitors.
   Google Scholar
• NELSON EM, TEWEY KM, LIU LF: Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinyl amino)-methanesulfon-m-anisidide. Proc. Natl. Acad. Sci. USA (1984) 81:1361–1365.
   PubMed Web of Science ®Google Scholar
• DENNY WA: Dual topoisomerase I/II poisons as anticancer drugs. Expert Opin. Invest. Drugs (1997) 6:1845–1851.
   PubMedGoogle Scholar
• POMMIER Y, JAXEL C, HEISE C, KERRIGAN D, KOHN KW: Structure-activity relationship of topoisomerase I inhibition by camptothecin derivatives: Evidence for the existence of a ternary complex. In: DNA topoisomerases in cancer. Potmesil M, Kohn KW (Eds.) Oxford University Press, New York (1991):121–132.
   Google Scholar
• HSIANG Y-H, HERTZBERG R, HECHT S, LIU LF: Campto-thecin induces protein-linked DNA breaks via mammalian DNA topoisomerase 1.1 Biol. Chem. (1985) 260:14873–14878.
   Google Scholar
• ••First publication describing topo I as the target forcamptothecin.
   Google Scholar
• MUGGIA FM, CREAVEN PJ, HANSEN HH, COHEN MH, SELAWRY OS: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880). Cancer Treat. Rep. (1972) 56(Part D:515–521.
   Google Scholar
• STEWART L, REDINBO MR, QIU X, HOL WGJ, CHAMPOUX JJ: A model for the mechanism of human topoisomerase I. Science (1998) 279:1534–1540.
   PubMed Web of Science ®Google Scholar
• ••First publication describing the tertiary structure oftopoisomerase I determined by x-ray crystallography.
   Google Scholar
• FAN Y, WEINSTEIN JN, KOHN KW, SHI LM, POMMIER Y: Molecular modeling studies of the DNA-topoisomerase i, ternary cleavable complex with Camptothecin. J. Merl. Chem. (1998) 41:2216–2226.
   PubMed Web of Science ®Google Scholar
• ACKERMAN P, GLOVER CVC, OSHEROFF N: Phosphory-lation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro. Proc. Natl. Acad. Sci. USA (1985) 82:3164–3168.
   PubMed Web of Science ®Google Scholar
• HUSAIN I, MOHLER JL, SEIGLER HF, BESTERMAN JM: Elevation of topoisomerase I messenger RNA, protein and catalytic activity in human tumors: demonstration of tumor-typespecificity and implications for cancer chemotherapy. Cancer Res. (1994) 54:539–546.
   PubMed Web of Science ®Google Scholar
• ••First published evidence of a correlation betweentopoisomerase I levels in human tumours and efficacy of therapy in the clinic.
   Google Scholar
• ARBUCK SG, TAKIMOTO CH: An overview of topoisomerase I-targeting agents. Semin. Hematol. (1998) 35:3–12.
   PubMed Web of Science ®Google Scholar
• ENG W-K, MCCABE FL, TAN KB et al.: Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol. (1990) 38:471–480.
   PubMed Web of Science ®Google Scholar
• WOESSNER RD, ENG W-K, HOFMANN GA et al.: Campto-thecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol. Res. (1992) 4:481–488.
   PubMed Web of Science ®Google Scholar
• ••Description of a highly camptothecin-resistant P388 cell linethat expresses little or no topoisomerase I.
   Google Scholar
• YOSHINARI T, MATSUMOTO M, ARAKAWA H eta].: Novelantitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(6-o-g lucopyr a nosy0-511.-indolo[2,3-a]pyrrolo [3,4-4 carbazole-5,7(611)-dione (BN-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res. (1995) 55:1310–1315.
   Google Scholar
• LONG BH, FAIRCHILD CA, BIFANO M, KRAMER R: Thecytotoxic mechanism of NB-506 involves action on both topoisomerase I and topoisomerase II. Proc. Amer. Assoc. Cancer Res. (1997) 38:75–70.
   Google Scholar
• PRUDHOMME M: Indolocarbazoles as anti-cancer agents. Curr. Pharm. Des. (1997) 3:265–290.
   Web of Science ®Google Scholar
• ••A very comprehensive review of indolocarbazoles and theiractions on topoisomerases and protein kinases as anticancer targets and for antiviral activities.
   Google Scholar
• SHAO R-G, CAO C-X, SHIMIZU T, O'CONNOR PM, KOHNKW, POMMIER Y: Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res. (1997) 57:4029–4035.
   PubMed Web of Science ®Google Scholar
• PINDUR U, KIM Y-S, MEHRABANI F: Advances in indolo[2,3-a]carbazole chemistry: design and synthesis of protein kinase C and topoisomerase I inhibitors. Curr. Med. Chem. (1999) 6:29–49.
   PubMed Web of Science ®Google Scholar
• BUSH JA, LONG BH, CATINO JJ, BRADNER WT, TOMITA K:Production and biological activity of rebeccamycin, a novel antitumor agent. J. Antibiot. (1987) 40:668–678.
   PubMed Web of Science ®Google Scholar
• •First publication describing rebeccamycin.
   Google Scholar
• LAM KS, FORENZA S, DOYLE TW, PEARCE CJ: Identifica-tion of indolepyruvic acid as an intermediate of rebeccamycin biosynthesis. J. Indust. Microbiol. (1990) 6:291–294.
   PubMedGoogle Scholar
• LAM KS, SCHROEDER DR, VEITCH JM, MATSON JA, FORENZA S: Isolation of a bromo analog of rebecca-mycin from Saccharothrix aerocolonigenes. J. Antibiot. (1991) 44:934–938.
   PubMed Web of Science ®Google Scholar
• MATSON JA, CLARIDGE C, BUSH JA et al: AT2433-A1,AT2433-A2, AT2433-B1 and AT2433-B2. Novel antitumor antibiotic compounds prod uced by Actino-madura melliaura - taxonomy, fermentation, isolation and biological properties. J. Antibiot. (1989) 42:1547–1555.
   Google Scholar
• QU X, CHAIRES JB, OHKUBO M, YOSHINARI T, NISHIMURA S, BAILLY C: A DNA-binding indolocarba-zole disaccharide derivative remains highly cytotoxic without inhibiting topoisomerase I. AntiCancer Drug Des. (2000) 15.
   Google Scholar
• WEITMAN S, MOORE R, BARRERA H, CHEUNG NK, IZBICKA E, VON HOFF DD: In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors. J. Ped. Hematol Oncol. (1998) 20:136–139.
   PubMed Web of Science ®Google Scholar
• KRISHNAN BS, MOORE ME, LAVOIE CP et al.: Fluores-cence polarization studies of the binding of BMS 181176 to DNA. J. Biomol Struct. Dynam. (1994) 12:625–636.
   PubMed Web of Science ®Google Scholar
• •Publication describing this unusually adventitious binding of BMS-181176 to DNA.
   Google Scholar
• KOHN KW: DNA as a target in cancer chemotherapy:measurement of macromolecular DNA damage produced in mammalian cells by anticancer agents and carcinogens. In: Methods In Cancer Research, Vol. XVI. DeVita VT, Busch H (Eds.) Academic Press, New York, USA (1979):291–345.
   Google Scholar
• KOHN KW, EWIG RAG, ERICKSON LC, ZWELLING LA: Measurement, of strand breaks and cross-links by alkaline elution. In. DNA Repair: A Laboratory Manual of Research Procedures, Vol. 1. Friedberg EC, Hanawalt PC (Eds.) Marcel Dekker New York, USA (1980:379–401.
   Google Scholar
• YAMASHITA Y, FUJII N, MURAKATA C, ASHIZAWA T, OKABE M, NAKANO H: Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry (1992) 31:12069–12075.
   PubMed Web of Science ®Google Scholar
• AKINAGA S, ASHIZAWA T, GOMI K et al: Antitumoreffect of KT6124, a novel derivative of protein kinase inhibitor K-252a and its mechanism of action. Cancer Chemother. Pharmacol. (1992) 29:266–272.
   PubMed Web of Science ®Google Scholar
• •First publication indicating that rebeccamycin and other indolocarbazoles are capable of inducing topoisomerase I mediated breaks in DNA.
   Google Scholar
• FUSE E, HANII H, KURATA N et al.: Unpredicted clinical pharmacology, of UCN-01 caused by specific binding to human ai-acid glycoprotein. Cancer Res. (1998) 58:3248–3253.
   PubMed Web of Science ®Google Scholar
• YOSHINARI T, YAMADA A, UEMURA D et al.: Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res. (1993) 53:490–494.
   PubMed Web of Science ®Google Scholar
• ARAKAWA H, IGUCHI T, MORITA M et al.: Novel indolo-carbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(6-n-glucopyranosyl)-5H -indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7(6W-dione (NB-506): its potent antitumor activities in mice. Cancer Res. (1995) 55:1316–1320.
   PubMed Web of Science ®Google Scholar
• FUKASAWA K, KOMATANI H, HARA Y et al.: Sequence-selective DNA cleavage by a topoisomerase I poison, NB-506. Int. J. Cancer (1998) 75:145–150.
   PubMed Web of Science ®Google Scholar
• OHKUBO M, KAWAMOTO H, OHNO T, NAKANO M, MORISHIMA H: Synthesis of NB-506, a new anticancer agent. Tetrahedron (1997) 53:585–592.
   Web of Science ®Google Scholar
• VANHOEFER U, VOIGT W, HILGER RA et al.: Cellular determinants of resistance to indolocarbazole analog 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(. beta.-n-glucopyranosyl)-511-indolo[2,3-alpha] pyrrolo[3,4-c]carbazole-5,7(6 11)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells. Oncol Res. (1997) 9:485–494.
   Google Scholar
• KANZAWA F, NISHIO K, KUBOTA N, SAIJO N: Antitumor activities of a new indolocarbazole substance, NB-506 and establishment of NB-506-resistant cell lines, SBC-3/NB. Cancer Res. (1995) 55:2806–2813.
   PubMed Web of Science ®Google Scholar
• OHE Y, TANIGAWARA Y, FUJII H et al.: Phase I and pharmacology study of 5-day infusion of NB-506 [abstract]. 33rd Annual Meeting of the American Society of Clinical Oncology (1997) 199.
   Google Scholar
• TAKENAGA N, ISHII M, NAKAJIMA S et al: In vivo metabo-lism of a new anticancer agent, 6-N-formylamino-12,13 -dihydr o -1, 11- dihydr oxy-13- (VD-glue° pyranosyl) 511-indolo [2,3-A]pyrrolo [3,4-C]carbazole-5,7(611)-dione (NB-506) in rats and dogs: pharmacoki-netics, isolation, identification and quantification of metabolites. Drug Metab. Dispos. (1999) 27:205–212.
   PubMed Web of Science ®Google Scholar
• TAKENAGA N, HASEGAWA T, ISHII M, ISHIZAKI H, HATA S, KAMEI T: In vitro metabolism of a new anticancer agent, 6-N-formylamino- 12,13-dihydro-1,11 -dihydroxy-13-(6-n-glucopyranosyl)511-indolo [2,3-A]pyrrolo [3,4-C]carbazole-5,7(611)-dione (NB-506), in mice, rats, dogs and humans. Drug Metab. Dispos. (1999) 27:213–220.
   PubMed Web of Science ®Google Scholar
• ZEMBOWER DE, ZHANG H, LINESWALA JP, KUFFEL MJ, AYTES SA, AMES MM: Indolocarbazole poisons of human topoisomerase I: regioisomeric analogs of ED-110. Bioorg. Med. Chem. Lett. (1999) 9:145–150.
   PubMed Web of Science ®Google Scholar
• OHKUBO M, NISHIMURA T, JONA H, HONMA T, NORISHIMA H: Practical synthesis of indolopyrrolocar-bazoles. Tetrahedron (1996) 52:8099–8112.
   Web of Science ®Google Scholar
• OHKUBO M, NISHIMURA T, JONA H, HONMA T, ITO S, MORISHIMA H: Synthesis of dissymmetric indolocarba-zole glycosides using the Mitsunobu reaction at the glycosylation step. Tetrahedron (1997) 53:5937–5950.
   Web of Science ®Google Scholar
• YOSHINARI T, ARAKAWA H, OKUBO M, MORISHIMA H,SUDA H, NISHIMURA S: New Indolocarbazole topoisomerase I inhibitors: their antitumor activity and mechanism of action [abstract]. The Eighth Confer-ence on DNA Topoisomerases in Therapy (1997) 12.
   Google Scholar
• FUKASAWA K, YOSHINARI T, OHKUBO M et al.: Antitumor activity and mechanism of new topoisomerase I inhibitor, ED-749 [abstract]. Proc. Amer. Assoc. Cancer Res. 1998, 39:81–80.
   Google Scholar
• J-107088 Banyu Pharmaceutical Co., Ltd. [abstract].Drug Report (1998).
   Google Scholar
• YOSHINARI T, OHKUBO M, FUKASAWA K et al.: Mode ofaction of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res. (1999) 59:4271–4275.
   PubMed Web of Science ®Google Scholar
• ARAKAWA H, MORITA M, KODERA T et al: Therapeuticeffects of a new antitumor indolocarbazole, ED-749, on human and marine tumors in mice [abstract]. Proc. Amer. Assoc. Cancer Res. (1998) 39:421–420.
   Google Scholar
• ARAKAWA H, MORITA M, KODERA T et al.: In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice. Jpn. J. Cancer Res. (1999) 90:1163–1170.
   PubMedGoogle Scholar
• PEREIRA ER, BELIN L, SANCELME M et al: Structure -activity relationships in a series of substituted indolo-carbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial proper-ties. J. Med. Chem. (1996) 39:4471–4477.
   PubMed Web of Science ®Google Scholar
• BAILLY C, RIOU J-F, COLSON P, HOUSSIER C,RODRIGUES-PEREIRA E, PRUDHOMME M: DNA cleavage by Topoisomerase I in the presence of indolocarba-zole derivatives of rebeccamycin. Biochemistry (1997) 36:3917–3929.
   PubMed Web of Science ®Google Scholar
• BAILLY C, COLSON P, HOUSSIER C, RODRIGUES-PEREIRAE, PRUDHOMME M, WARING MJ: Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin. Mol. Pharmacol. (1998) 53:77–87.
   PubMed Web of Science ®Google Scholar
• LABOURIER E, RIOU J-F, PRUDHOMME M, CARRASCO C,BAILLY C, TAZI J: Poisoning of topoisomerase I by an antitumor indolocarbazole drug: Stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity. Cancer Res. (1999) 59:52–55.
   PubMed Web of Science ®Google Scholar
• ROSSI F, LABOURIER E, FORNE T et al: Specific phospho-rylation of SR proteins by mammalian DNA topoisomerase I. Nature (London) (1996) 381:80–82.
   PubMed Web of Science ®Google Scholar
• ANIZON F, MOREAU P, SANCELME M et al.: Syntheses, biochemical and biological evaluation of stauro-sporine analogs from the microbial metabolite rebeccamycin. Bioorg. Med. Chem. (1998) 6:1597–1604.
   PubMed Web of Science ®Google Scholar
• MOREAU P, SANCELME M, PRUDHOMME M et al.: Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent. J. Med. Chem. (1999) 42:584–592.
   PubMed Web of Science ®Google Scholar
• MOREAU P, ANIZON F, SANCELME M et al.: Synthesis,mode of action and biological activities of rebecca-mycin bromo derivatives. J. Med. Chem. (1999) 42:1816–1822.
   PubMed Web of Science ®Google Scholar
• BAILLY C, DASSONNEVILLE L, COLLSON P, HOUSSIER C,FUKASAWA K, NISHIMURA S: Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents. Cancer Res. (1999) 59:2853–2860.
   PubMed Web of Science ®Google Scholar
• BAILLY C, QU X, CHAIRES JB et al.: Substitution at theF-Ring N-Imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding and topoisomerase I inhibition activities. J. Med. Chem. (1999) 26233.
   Web of Science ®Google Scholar
• BAILLY C, QU X, ANIZON F, PRUDHOMME M, RIOU J-F,CHAIRES JB: Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue. Mol. Pharmacol. (1999) 55:377–385.
   PubMed Web of Science ®Google Scholar
• BAILLY C, QU X, GRAVES DE, PRUDHOMME M, CHAIRESJB: Calories from carbohydrates: energetic contribu-tion of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition. Chem. Biol. (1999) 6:277–286.
   PubMedGoogle Scholar
• KANEKO T, WONG H, UTZIG J, SCHURIG J, DOYLE TW:Water soluble derivatives of rebeccamycin. j Antibiot. (1990) 45:125–127.
   Google Scholar
• CHEN AY, YU C, GATTO B, LIU LF: DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Natl. Acad. Sci. USA (1993) 90:8131–8135.
   PubMed Web of Science ®Google Scholar
• CHEN AY, YU C, BODLEY A, PENG LF, LIU LF: A newmammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res. (1993) 53:1332–1337.
   PubMed Web of Science ®Google Scholar
• SUN Q, GATTO B, YU C, LIU A, LIU LF, LAVOIE EJ:Structure activity of topoisomerase I poisons related to Hoechst 33342. Bioorg. Med. Chem. Lett. (1994) 4:2871–2876.
   Web of Science ®Google Scholar
• KIM JS, SUN Q, GATTO B et al.: Structure-activityrelationships of benzimidazoles and related heterocy-cles as topoisomerase I poisons. Bioorg. Med. Chem. (1996) 4:621–630.
   PubMed Web of Science ®Google Scholar
• KIM JS, GATTO B, YU C, LIU A, LIU LF, LAVOIE EJ: Substi-tuted 2,5'-Bi-1H-benzimidazoles: Topoisomerase I Inhibition and Cytotoxicity. J. Med. Chem. (1999) 39:992–998.
   Google Scholar
• SUN Q, GATTO B, YU C, LIU A, LIU LF, LAVOIE EJ:Synthesis and evaluation of terbenzimidazoles as topoisomerase I inhibitors. J. Med. Chem. (1995) 38:3638–3644.
   PubMed Web of Science ®Google Scholar
• KIM JS, SUN Q, YU C, LIU A, LIU LF, LAVOIE EJ: Quantita-tive structure-activity relationships on 5-substituted terbenzimidazoles as topoisomerase I poisons and antitumor agents. Bioorg. Med. Chem. (1998) 6:163–172.
   PubMed Web of Science ®Google Scholar
• KIM JS, YU C, LIU A, LIU LF, LAVOIE EJ: Terbenzimida-zoles: influence of 2"-, 4- and 5-substituents on cytotoxicity and relative potency as topoisomerase I poisons. J. Med. Chem. (1997) 40:2818–2824.
   PubMed Web of Science ®Google Scholar
• PILCH DS, XU Z, SUN Q et al: Characterizing the DNA binding modes of a topoisomerase I - poisoning terbenzimidazole: evidence for both intercalative and minor groove binding properties. Drug Des. Disc. (1996) 13:115–133.
   PubMedGoogle Scholar
• PILCH DS, XU Z, SUN Q, LAVOIE EJ, LIU LF, BRESLAUER KJ:A terbenzimidazole that preferentially binds and conformationally alters structurally distinct DNA duplex domains: a potential mechanism for topoisomerase I poisoning. Proc. Natl Acad. Sci. USA (1997) 94:13565–13570.
   PubMed Web of Science ®Google Scholar
• XU Z, LI T-K, KIM JS et al: DNA minor groove binding-directed poisoning of human DNA topoisomerase I by terbenzimidazoles. Biochemistry (1998) 37:3558–3566.
   PubMed Web of Science ®Google Scholar
• HERTZBERG RT, CARANFA MJ, HECHT SM: On the mechanism of topoisomerase I inhibition by campto-thecin: evidence for binding to an enzyme-DNA complex [abstract]. Biochemistry (1989) 28:4626–4638.
   Web of Science ®Google Scholar
• GATTO B, SANDERS MM, YU C et al.: Identification oftopoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. Cancer Res. (1996) 56:2795–2800.
   PubMed Web of Science ®Google Scholar
• MAKHEY D, GATTO B, YU C, LIU A, LIU LF, LAVOIE EJ:Coralyne and related compounds as mammalian topoisomerase I and topoisomerase II poisons. Bioorg. Med. Chem. (1996) 4:781–791.
   PubMed Web of Science ®Google Scholar
• PILCH DS, YU C, MAKHEY D et al.: Minor groove-directed and intercalative ligand-DNA interactions in the poisoning of human dna topoisomerase i by protoberberine analogs. Biochemistry (1997) 36:12542–12553.
   PubMed Web of Science ®Google Scholar
• SANDERS MM, LIU AA, LI T-K et al.: Selective cytotoxicityof topoisomerase-directed protoberberines against glioblastoma cells. Biochem. Pharmacol. (1998) 56:1157–1166.
   PubMed Web of Science ®Google Scholar
• PAULL KD, HAMEL E, MALSPEISIS L: Prediction of the Biochemical Mechanism of Action from the In vitro Antitu-mour Screen of the National Cancer Institute. American Chemical Society, Washington, DC. USA (1995).
   Google Scholar
• BOYD MR, PAULL KD: Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. (1995) 34:91–109.
   Web of Science ®Google Scholar
• KOHLHAGEN G, PAULL KD, CUSHMAN M, NAGAFUJI P,POMMIER Y: Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. Mol. Pharmacol. (1998) 54:50–58.
   PubMed Web of Science ®Google Scholar
• STRUMBERG D, POMMIER Y, PAULL K, JAYARAMAN M,NAGAFUJI P, CUSHMAN M: Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. J. Med. Chem. (1999) 42:446–457.
   PubMed Web of Science ®Google Scholar
• JAYARAMAN M, FANWICK PE, CUSHMAN M: Novel oxidative transformation of indenoisoquinolines to isoquinoline-3-spiro-3'-phthalides in the presence of osmium tetraoxide and 4-methylmorpholine N-oxide. J. Org. Chem. (1998) 63:5736–5737.
   PubMed Web of Science ®Google Scholar
• CUMMINGS J, MACPHERSON JS, MEIKLE I, SMYTH JF: Development of anthracenyl-amino acid conjugates as topoisomerase land II inhibitors that circumvent drug resistance. Biochem. Pharmacol. (1996) 52:979–990.
   PubMed Web of Science ®Google Scholar
• CUMMINGS J, HADFIELD JA, MEIKLE I, MCGOWN AT, SMYTH JF: Molecular modeling of the interaction of anthracenyl-amino acid topoisomerase inhibitors with the DNA sequence d(CGTACG). Anti Cancer Drugs (1996) 7:636–641.
   PubMed Web of Science ®Google Scholar
• MEIKLE I, CUMMINGS J, MACPHERSON JS, SMYTH JF: Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs. AntiCancer Drug Des. (1995) 10:515–527.
   PubMedGoogle Scholar
• MEIKLE I, CUMMINGS J, MACPHERSON JS, HADFIELD JA,SMYTH JF: Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates. Biochem. Pharmacol. (1995) 49:1747–1757.
   PubMed Web of Science ®Google Scholar
• CUMMING JN, MEIKLE I, MACPHERSON J, SMYTH J: Accumulation of anthracenyl-amino acid topoisomerase land II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance likquid chromatog-raphy. Cancer Chem other. Pharmacol (1995) 37:103–109.
   PubMed Web of Science ®Google Scholar
• CUMMING JN, SUMNER AT, SLAVOTINEK A, MEIKLE I,MACPHERSON J, SMYTH JF: Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenyl-amino acid topoisomerase II catalytic inhibitor NU/ICRF 500. Mutat. Res. (1995) 344:55–62.
   PubMedGoogle Scholar
• MACPHERSON JS, CUMMINGS J, MEIKLE I, MILLER EP,SMYTH JF: Cell cycle effects of the novel topoisomerase I, inhibitor NU/ICRF 505 in a panel of Chinese hamster ovary, cell lines. Eur. J. Cancer (1997) 33:280–283.
   PubMed Web of Science ®Google Scholar
• MEIKLE I, CUMMINGS J, MACPHERSON J, SMYTH J: Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505. Br. J. Cancer (1996) 74:374–379.
   PubMed Web of Science ®Google Scholar
• YAMASHITA Y, KAWADA S, FUJII N, NAKANO H: Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Biochemistry (1991) 30:5838–5845.
   PubMed Web of Science ®Google Scholar
• FUJII N, YAMASHITA Y, CHIBA S et al.: UCE6, a newantitumor antibiotic with topoisomerase I mediated DNA cleavage activity, from actinomycetes. J. Antibiol (1993) 46:1173–1174.
   PubMed Web of Science ®Google Scholar
• FUJII N, YAMASHITA Y, ANDO T et al.: UCE1022, a newantitumor antibiotic with topoisomerase I mediated DNA cleavage activity from Paeclipmyces. J. AntibioL (1994) 47:949–951.
   PubMedGoogle Scholar
• FUJII N, YAMASHITA Y, MIZUKAMI T, NAKANO H: Correlation between the formation of cleavable complex with topoisomerase I and growth-inhibitory activity, for saintopin-type antibiotics. Mol. Pharmacol (1997) 51:269–276.
   PubMed Web of Science ®Google Scholar
• INABA M, MITSUHASHI J, KAWADA S, NAKANO H: Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis. Jpn. J. Cancer Res. (1994) 85:187–193.
   PubMedGoogle Scholar
• FUJII N, TANAKA F, YAMASHITA Y, ASHIZAWA T, CHIBA S, NAKANO H: UCE6, a new antitumor antibiotic with topoisomerase I -mediated DNA cleavage activity, produced by actinomycetes: producing organism. J. Antibiot. (1997) 50:490–495.
   PubMed Web of Science ®Google Scholar
• SIM S-P, GATTO B, YU C et al.: Differential poisoning of topoisomerases by menogaril and nogalamycin dictated by the minor groove-binding nogalose sugar. Biochemistry (1997) 36:13285–13291.
   PubMed Web of Science ®Google Scholar
• ABDALLAH F, DROZD M, GIETZEN K: Inhibition of cell proliferation by the novel dihydropyrimidine deriva-tive B859-35 [abstract]. J. Cancer Res. Clin. Oncol (1990) 116(Suppl.):446.
   Google Scholar
• STRAUB T, BOESENBERG C, GEKELER V, BOEGE F: The dihydropyridine dexniguldipine hydrochloride inhibits cleavage and religation reactions of eukary-otic DNA topoisomerase I. Biochemistry (1997) 36:10777–10783.
   PubMed Web of Science ®Google Scholar
• SCHULLER HM, CORREA E, ORLOFF M, REZNIK GK: Successful chemotherapy of experimental neuroen-docrine lung tumors in hamsters with an antagonist of Ca2±/calmodulin. Cancer Res. (1990) 50:1645–1649.
   PubMed Web of Science ®Google Scholar
• SCHULLER HM, ORLOFF M, REZNIK GK: Inhibition of protein-kinase-C - Dependent cell proliferation of human lung cancer cell lines by the dihydropyridine dexniguldipine. J. Cancer Res. Clin. Oncol. (1994) 120:354–358.
   PubMed Web of Science ®Google Scholar
• ÜBERALL F, MALY K, EGLE A, DOPPLER W, HOFFMANN J, GRUNICKE HH: Inhibition of cell proliferation, protein kinase C and phorbolester-induced fos expression by the dihydropyridine derivative B859-35 [abstract]. Cancer Res. (1991) 51:5821–5825.
   PubMed Web of Science ®Google Scholar
• AfIALO E, IFTACH S, SEGAL S, GAZIT A, PRIEL E: Inibition of topoisomerase I activity by tyrphostin derivatives, protein tyrosine kinase blockers: mechanism of action [abstract]. Cancer Res. (1994) 54:5138–5142.
   PubMed Web of Science ®Google Scholar
• Summary of results: dexniguldipine, ecteinascidin 743, ED749, NB 506, NSC 314622, NU-ICRF 505, UCE 1022, UCE 6 [abstract]. Adis R&D Insight (1999).
   Google Scholar
• Summary of search results: ecteinascidin 743, NB-506, ED-749 [abstract]. Adis R&D Insight (2000).
   Google Scholar
• RINEHART KL, HOLT TG, FREGEAU NL et al.: Bioactive compounds from aquatic and terrestrial sources. J. Nat. Products (1990) 53:771–792.
   PubMed Web of Science ®Google Scholar
• RINEHART KL, SAKAI R, HOLT TG et al.: Biologically active natural products. Pure Appl. Chem. (1990) 62:1277–1280.
   Web of Science ®Google Scholar
• RINEHART KL, HOLT TG, FREGEAU NL et al: Ecteinas-cidins 729, 743, 745, 759A, 759B and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J. Org. Chem. (1990) 55:4512–4515.
   Web of Science ®Google Scholar
• WRIGHT AE, FORLEO DA, GUNAWARDANA GP, GUNASEDERA SP, KOEHN FE, MCCONNELL 0J: Antitumor tetrahydroisoquinoline alkaloids from the colonial Ascidian Ecteinascidia turbinata. JOrg.Chem. (1990) 55:4508–4512.
   Web of Science ®Google Scholar
• SAKAI R, RINEHART KL, GUAN Y, WANG AHJ: Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities in vivo. Proc. Natl. Acad. Sci. USA (1992) 89:11456–11460.
   PubMed Web of Science ®Google Scholar
• MARTINEZ EJ, OWA T, SCHREIBER SL, COREY EJ: Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinas-cidin 743. Proc. Natl. Acad. Sci. USA (1999) 96:3496–3501.
   PubMed Web of Science ®Google Scholar
• POMMIER Y, KOHLHAGEN G, BAILLY C, WARING M, MAZUMDER A, KOHN KW: DNA sequence- and structure-selective alkylation of Guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry (1996) 35:13303–13309.
   PubMed Web of Science ®Google Scholar
• ZEWAIL-FOOTE M, HURLEY LH: Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J. Med. Chem. (1999) 42:2493–2497.
   PubMed Web of Science ®Google Scholar
• BONFANTI M, LA VALLE E, FARO JMFS et al: Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. AntiCancer Drug Des. (1999) 14:179–186.
   PubMedGoogle Scholar
• SAKAI R, JARES-ERIJMAN EA, MANZANARES I, SILVA ELIPE MV, RINEHART KL: Ecteinascidins: putative biosyn-thetic precursors and absolute stereochemistry. J. Am. Chem. Soc. (1996) 118:9017–9023.
   Web of Science ®Google Scholar
• TAKEBAYASHI Y, POURQUIER P, YOSHIDA A, KOHLHAGEN G, POMMIER Y: Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc. Natl. Acad. Sci. USA (1999) 96:7196–7201.
   PubMed Web of Science ®Google Scholar
• COREY EJ, GIN DY, KANIA RS: Enantioselective total synthesis of ecteinascidin 743. J. Am. Chem. Soc. (1996) 118:9202–9203.
   Web of Science ®Google Scholar
• ANDOH T, ISHIDA R: Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta (1998) 1400:155–171.
   PubMed Web of Science ®Google Scholar
• SUZUKI K, SIDDIQUE T, NISHIMURA H, SEKIMOTO J, UYEDA M: Inhibition of DNA topoisomerases by microbial inhibitors [abstract]. JEnzyme Inhib. (1998) 13:41–55.
   PubMed Web of Science ®Google Scholar
• POMMIER Y: Topoisomerase inhibitors: why develop new ones? Curr. Opin. Oncol. End. Met. Invest. Drugs (1999) 1:168–169.
   Google Scholar
• Cumulative NCE introduction index, 1983-1998 [abstract]. Ann. Rep. Med. Chem. (1999) 34:383–413.
   Google Scholar